Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-mesothelin CAR-NK cells
- Development stage
- Phase 1
- Lead developer
- Beijing Allife Medicine Technology
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anti-mesothelin CAR-NK cells are a type of engineered cellular immunotherapy in which natural killer (NK) cells are modified ex vivo to express a chimeric antigen receptor (CAR) that specifically targets mesothelin, a cell surface antigen commonly overexpressed in several solid tumors such as ovarian cancer, mesothelioma, pancreatic cancer, and some lung cancers. The typical CAR construct includes an extracellular single-chain variable fragment (scFv) recognizing mesothelin, a transmembrane domain, co-stimulatory signaling domains such as 2B4, and a CD3ζ signaling domain. These enhancements potentiate NK cell cytotoxicity against tumor cells expressing mesothelin. Anti-mesothelin CAR-NK cells may be derived from various sources, including umbilical cord blood, induced pluripotent stem cells (iPSCs), or NK cell lines. Preclinical studies have shown potent anti-tumor activity in models of ovarian cancer with low toxicity, and clinical trials are ongoing to assess safety and efficacy in humans[7].
- Other names
- mesothelin-targeted CAR-NK cells
02
Targets
Mesothelin
Beyond the preview
Go deeper on anti-mesothelin CAR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-mesothelin CAR-NK cells.